Company Performance Metrics
- Robert N. Young: Founder & President
- Jonathan Polak: Chief Executive OfficerPast Role: 1Datapoint Diagnostics, CEO
Mesentech is a company focused on treating diseases and medical conditions that relate to bone. They are generating a series of products, from different, but complementary approaches that will effectively address currently difficult to treat conditions.
Bone can be one of the most difficult organs to access and treat with medicines. It’s hard
surface and low porosity presents challenges in adequately getting drugs to either the bone surface or to its interior. Treatment often requires administering high doses of a drug over extended periods. Not only is achievement of efficacy compromised, but also side- effects may be more prevalent and can limit treatment effectiveness.
Mesentech’s lead technology is a proprietary bone targeting system that can effectively deliver small-molecule and biological drugs to the surface or to the interior of bone. Pre-clinical in-vivo models have confirmed the utility of this technology.
